Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease (DUOGLOBE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02611713
Recruitment Status : Recruiting
First Posted : November 23, 2015
Last Update Posted : May 6, 2019
Sponsor:
Information provided by (Responsible Party):
AbbVie

Brief Summary:
This study is a non-interventional post-marketing observational study (PMOS) of participants with advanced Parkinson's disease (PD) treated with Duodopa/Duopa in a routine clinical setting. Effectiveness of treatment will be collected with physician and participant/caregiver health outcomes beginning with PMOS enrollment (baseline visit), at the start of Duodopa/Duopa treatment via percutaneous endoscopic gastrostomy-with jejunal extension (PEG-J), at regularly scheduled visits closest to Months 3 and 6, and every 6 months thereafter up to 36 months. An additional cohort of participants will be enrolled who in addition will be evaluated with a wearable device.

Condition or disease
Advanced Parkinson's Disease

Layout table for study information
Study Type : Observational
Estimated Enrollment : 243 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: DUOdopa/Duopa in Patients With Advanced Parkinson's Disease (PD) - a GLobal Observational Study Evaluating Long-Term Effectiveness (DUOGLOBE)
Actual Study Start Date : January 4, 2016
Estimated Primary Completion Date : March 27, 2021
Estimated Study Completion Date : March 27, 2021

Resource links provided by the National Library of Medicine


Group/Cohort
Arm A: Participants with Advanced Parkinson's Disease
Participants who along with their physicians have elected for treatment with Duodopa/Duopa and are prescribed according to the local product label and reimbursement guidelines for their participating countries.
Arm B: Participants with Advanced Parkinson's Disease
Participants who along with their physicians have elected for treatment with Duodopa/Duopa and are prescribed according to the local product label and reimbursement guidelines for their participating countries. Participants will be evaluated with a wearable device



Primary Outcome Measures :
  1. Change in the number of hours spent in OFF time in Arm A [ Time Frame: Baseline visit (Enrollment) to month 36 ]
    Assess the effectiveness of Duodopa/Duopa treatment on OFF time measured by the change (from baseline to 36 months) in the number of hours spent in OFF time as reported by the participant for the day prior to the clinical visit.

  2. Change in Duration of OFF time (hours/day) in Arm B [ Time Frame: Baseline visit (Enrollment) to month 6 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 6 months) in OFF time duration as measured by UPDRS Part IV (Motor Symptoms), item 39.

  3. Change in Duration of OFF time (hours/day) in Arm B [ Time Frame: Baseline visit (Enrollment) to month 6 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 6 months) in OFF time duration as reported by participant with PD Diary both per full 24 hours and for the time period of 09:00 - 18:00

  4. Duration of bradykinesia score above target in Arm B [ Time Frame: Baseline visit (Enrollment) to month 6 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 6 months) in duration of bradykinesia score above target between 09:00 - 18:00 and for the full 24 hours per day (measured by Parkinson's KinetiGraph ( PKG))

  5. Average bradykinesia score in Arm B [ Time Frame: Baseline visit (Enrollment) to month 6 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 6 months) in average bradykinesia score (measured by PKG)


Secondary Outcome Measures :
  1. Change in Disease-Specific Caregiver Burden in Arm A [ Time Frame: Baseline visit (Enrollment) to month 36 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in disease-specific caregiver burden as measured by the Modified Caregiver Strain Index (MCSI) for PD with a total score range from 0 to 26.

  2. Change in the Duration of Dyskinesia in Arm A [ Time Frame: Baseline visit (Enrollment) to month 36 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in duration of dyskinesia as reported by the patient for the day prior to the clinical visit

  3. Change in Disease-Specific Sleep Quality in Arm A [ Time Frame: Baseline visit (Enrollment) to month 36 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in disease-specific sleep quality as measured by Parkinson's Disease Sleep Scale-2 (PDSS-2) with a total score range from 0 to 60.

  4. Change in Tremor Severity in Arm A [ Time Frame: Baseline visit (Enrollment) to month 36 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in tremor severity as measured by UPDRS Part III, item 20 (Tremor at Rest) with a total score range of 0 to 20.

  5. Change in Motor Function in Arm A [ Time Frame: Baseline visit (Enrollment) to month 36 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in motor function as measured by UPDRS, Part III (Motor Examination) with a total score range of 0 to 108.

  6. Change in Generic Quality of Life in Arm A [ Time Frame: Baseline visit (Enrollment) to month 36 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in generic quality of life as measured by EuroQoL-5 Dimensions Quality of Life Questionnaire (EQ-5D). This assessment contains a health state descriptive part with five items scored from 1 to 3.

  7. Change in Dyskinesia Severity in Arm A [ Time Frame: Baseline visit (Enrollment) to month 36 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in dyskinesia severity as measured by Unified Dyskinesia Rating Scale (UDysRS) with a total score range from 0 to 104.

  8. Change in Overall Clinical Impression of Disease Severity in Arm A [ Time Frame: Baseline visit (Enrollment) to month 36 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in overall clinical impression of disease severity as measured by Clinical Impression of Severity Index for Parkinson's Disease (CISI-PD) obtained by adding four domain scores with a total score range from 0 to 24.

  9. Change in Disease-Specific Quality of Life in Arm A [ Time Frame: Baseline visit (Enrollment) to month 36 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in disease-specific quality of life (QoL) as measured by Parkinson's Disease Questionnaire 8 (PDQ-8) summary index range from 0 to 100.

  10. Change in OFF Time Duration in Arm A [ Time Frame: Baseline visit (Enrollment) to month 36 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in OFF time duration as measured by UPDRS Part IV (Motor Fluctuations), item 39, with a total score range of 0 to 4.

  11. Change in Non-Motor Symptoms in Arm A [ Time Frame: Baseline visit (Enrollment) to month 36 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in non-motor symptoms as measured by Non-Motor Symptoms Scale (NMSS) with a total score range from 0 to 360.

  12. Change in Healthcare Resource Utilization in Arm A [ Time Frame: Baseline visit (Enrollment) to month 36 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in healthcare resource utilization as measured by the Healthcare Resource Utilization Questionnaire (HCRU).

  13. Change in Daytime Sleepiness in Arm A [ Time Frame: Baseline visit (Enrollment) to month 36 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in daytime sleepiness as measured by Epworth Sleepiness Scale (ESS) with a total score range from 0 to 24.

  14. Change in Activities of Daily Living in Arm A [ Time Frame: Baseline visit (Enrollment) to month 36 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in Activities of Daily Living as measured by Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activity of Daily Living) with a total score range of 0 to 52.

  15. Change in Complications of Therapy in Arm A [ Time Frame: Baseline visit (Enrollment) to month 36 ]
    Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in Complications of Therapy (dyskinesia duration, disability, pain and early morning dystonia) as measured by UPDRS Part IV (Complications of Therapy), items 32 (individual score 0 to 4), 33 (individual score 0 to 4), 34 (individual score 0 to 4), 35 (individual score 0 to 1) and total score range of 0 to 13.

  16. Correlation of non-motor and motor improvements with Quality of Life improvements in Arm A [ Time Frame: Baseline visit (Enrollment) to month 36 ]
    Assess the correlation of non-motor and motor improvements with the improvement in the Quality of Life (QOL).

  17. Correlation between duration of OFF time measured by UPDRS IV and duration of bradykinesia score above target in Arm B [ Time Frame: Baseline visit (Enrollment) to month 6 ]
    Assess the correlation between duration of OFF time measured by UPDRS IV item 39 and duration of bradykinesia score above target between 09:00 - 18:00 and for the full 24 hours per day measured by PKG

  18. Correlation between duration of OFF time measured by patient with PD Diary and average bradykinesia score in Arm B [ Time Frame: Baseline visit (Enrollment) to month 6 ]
    Assess the correlation between duration of OFF time measured by patient with PD Diary both per full 24 hours and for the time period of 09:00 - 18:00 and average bradykinesia score measured by PKG

  19. Correlation between duration of bradykinesia score above target and average bradykinesia score in Arm B [ Time Frame: Baseline visit (Enrollment) to month 6 ]
    Assess the correlation between duration of bradykinesia score above target between 09:00 - 18:00 and for the full 24 hours per day measured by PKG and average bradykinesia score measured by PKG

  20. Correlation between duration of OFF time measured by patient with PD Diary and duration of bradykinesia score above target in Arm B [ Time Frame: Baseline visit (Enrollment) to month 6 ]
    Assess the correlation between duration of OFF time measured by patient with PD Diary both per full 24 hours and for the time period of 09:00 - 18:00 and duration of bradykinesia score above target between 09:00 - 18:00 and for the full 24 hours per day measured by PKG

  21. Correlation between duration of OFF time measured by UPDRS IV and average bradykinesia score in Arm B [ Time Frame: Baseline visit (Enrollment) to month 6 ]
    Assess the correlation between duration of OFF time measured by UPDRS IV item 39 and average bradykinesia score measured by PKG

  22. Correlation between duration of dyskinesia and Unified Dyskinesia Rating Scale (UDysRS) in Arm B [ Time Frame: Baseline visit (Enrollment) to month 6 ]
    Pairwise correlation between duration of dyskinesia both per full 24 hours and 09:00 - 18:00 (based on UPDRS IV, PD diary and dyskinesia score measured by PKG) and UDysRS will be evaluated

  23. Severity of dyskinesia in Arm B [ Time Frame: Baseline visit (Enrollment) to month 6 ]
    Severity of dyskinesia (item 33 score of UPDRS IV, UDysRS total score or the PKG-based dyskinesia score and the pairwise correlation between these will be evaluated

  24. Motor symptoms in Arm B [ Time Frame: Baseline visit (Enrollment) to month 6 ]
    Motor symptoms measured by UPDRS III in ON state and correlation with PKG-based bradykinesia score will be evaluated

  25. Severity of tremor in Arm B [ Time Frame: Baseline visit (Enrollment) to month 6 ]
    Severity of tremor measured by item 20 of UPDRS III in ON state and PKG-based tremor score and correlation between both will be evaluated

  26. Activities of Daily Living (ADL) in Arm B [ Time Frame: Baseline visit (Enrollment) to month 6 ]
    ADL measured by UPDRS II in ON state and correlation with and PKG-based fluctuation/dyskinesia score and bradykinesia score will be evaluated

  27. Sleep in Arm B [ Time Frame: Baseline visit (Enrollment) to month 6 ]
    Sleep as measured by PDSS-2, sleep/fatigue subdomain of NMSS, duration of sleep based on PD Diary or PKG-based night-time total sleep and pairwise correlation between these will be evaluated

  28. Daytime sleepiness in Arm B [ Time Frame: Baseline visit (Enrollment) to month 6 ]
    Daytime sleepiness as measured by PKG-based percent of time asleep in the day time and the Epworth Sleepiness Scale and the correlation between these will be evaluated

  29. Quality of Life (QoL) in Arm B [ Time Frame: Baseline visit (Enrollment) to month 6 ]
    QoL as measured by PDQ-8 and the correlation with PKG-based fluctuation/dyskinesia and bradykinesia scores will be evaluated



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Advanced Parkinson's disease
Criteria

Inclusion Criteria:

  • Eligibility for Duodopa/Duopa therapy in accordance with the approved local Duodopa/Duopa label in the participating country.
  • Duodopa/Duopa naïve participants
  • Decision to treat with Duodopa/Duopa made by the physician prior to any decision to approach the participant to participate in this study
  • Prior to any study-related procedures being performed, the participant, or legal authorized representative (LAR) has voluntarily signed an Authorization for Use/Disclosure of Data (AUDD)/informed consent form (ICF) according to national regulations after the study has been explained and the subject has had the opportunity to have questions answered.
  • For Arm B: Participant and caregiver must be motivated to use the PKG, understand the instructions and be able to handle the device.
  • For Arm B: participant must demonstrate at least 75% concordance with the investigator's or qualified designee's assessment of symptoms on the Parkinson's disease diary following training at enrollment visit 1/V1 with concordance on at least 1 time interval of "Off", concordance on at least 1 time interval of "ON regardless of dyskinesia" and at least 1 time interval of "ON with dyskinesia" irrespective of whether the dyskinesia are troublesome or not troublesome.

Exclusion Criteria:

  • Any condition included in the contraindications section of the approved local Duodopa/Duopa label in the participating country.
  • Participants who have had previous surgery for PD including, but not limited to deep brain stimulation (DBS) or cell transplantation (this criterion removed for US sites for Arm A).
  • Participants currently in treatment with continuous apomorphine infusion. In case of a previous treatment with continuous subcutaneous apomorphine infusion, there must be at least 4 weeks between discontinuation of this treatment and inclusion into this study.
  • Mini-Mental State Examination (MMSE) score <24
  • Participation in a concurrent interventional clinical trial.
  • Lack of motivation or insufficient language skills to complete the study questionnaires

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02611713


Contacts
Layout table for location contacts
Contact: Debra Cardoni +18479389182 debbie.cardoni@abbvie.com
Contact: Sabir Patel sabir.patel@abbvie.com

  Show 54 Study Locations
Sponsors and Collaborators
AbbVie
Investigators
Layout table for investigator information
Study Director: AbbVie Inc. AbbVie

Additional Information:
Layout table for additonal information
Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT02611713     History of Changes
Other Study ID Numbers: P14-494
First Posted: November 23, 2015    Key Record Dates
Last Update Posted: May 6, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by AbbVie:
Advanced Parkinson's Disease
Duodopa/Duopa
carbidopa levodopa enteral suspension (CLES)
levodopa-carbidopa intestinal gel (LCIG)
OFF time
motor and non-motor symptoms
dyskinesia
tremor
Quality of Life
Observational
Long-term
Caregiver Burden
effectiveness
fluctuations
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Levodopa
Carbidopa
Carbidopa, levodopa drug combination
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Aromatic Amino Acid Decarboxylase Inhibitors
Enzyme Inhibitors
Adjuvants, Immunologic
Immunologic Factors
Dopamine Agonists